Novartis said its in-development skin cancer drug aced a Phase II study, completely eradicating the disease in some patients, and now the company plans to loop in regulators, possibly signaling an early FDA application for the treatment.
Prosecutors came knocking at Novartis' Tokyo offices, stepping up their probe of the Swiss drugmaker's Diovan advertising. The Japanese authorities raided the local unit as part of an investigation into allegations that Diovan data was manipulated, and advertising for the blood pressure drug relied on that rigged data.
While the meningitis B outbreak has died down, the debate it stirred up continues. This week researchers at the Manhattan Institute weighed in with their opinion: If a vaccine is good enough for Europe, it is good enough for the U.S..
The French biotech announced this morning that it will collaborate with Paris-based Cellectis on UCART19, an engineered T cell with a chimeric antigen receptor for leukemia and lymphomas, as well as 5 other such programs. Servier is paying Cellectis $10 million down and up to $140 million per program in milestones in its gamble on the biotech's approach.
Novartis is gobbling up a startup biotech in the U.S. that could help provide an entry into the frenzied race for PD-1 targeting therapies, announcing this morning that it had struck a deal to buy CoStim Pharmaceuticals, a low-profile biotech based in Cambridge, MA, and listed as part of Atlas Venture's group of companies.
Novartis may have a long way to go before it's done cutting its blockbuster R&D budget. With a major strategic review underway, Novartis CEO Joe Jimenez told analysts that its massive drug research operation still offers a fresh source of spending cuts--even after a number of moves aimed at concentrating more of its R&D operations in the company's main research hubs in the U.S., Europe and Asia.
Want the latest on Novartis' should-we-or-shouldn't-we asset review? Leerink Partners analysts met with CEO Joe Jimenez recently, so they can deliver that and more, including some hints at cost-cutting targets.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...
Novartis is expanding a plant in Singapore and the international engineering and construction firm PM Group is helping.
Last week Novartis' vaccine unit posted yet another operating loss, extending its streak in the red to four years. Yet despite its well-known, long-term problems, suitors are reportedly circling the unit, with the potential of Bexsero and Menveo likely to be a factor attracting potential buyers.